Roelck A Cuperus, VP Regulatory Affairs, joined Prosensa in December 2008 and is responsible for the directing worldwide regulatory activities pertaining to the development of oligonucleotides in several diseases, amongst others Duchenne Muscular Dystrophy.
Roelck has almost 15 years of regulatory experience with various biotechnology and pharmaceutical companies, including Genzyme and Genencor (a Danisco Division). Roelck received her PhD in Chemistry (specialisation Biochemistry) from the University of Amsterdam, The Netherlands.